Novo Nordisk Research Centre Oxford (NNRCO) was launched in 2017 as a strategic alliance between Oxford University, a global leader in metabolism research, and Novo Nordisk, the leading diabetes therapeutics company.
The purpose of this alliance is to build upon the longstanding relationship between Oxford University and Novo Nordisk. This will be achieved by establishing a landmark collaboration for the advancement of the type 2 diabetes research working towards innovative medicines that that make a difference in the lives of patients with diabetes. The alliance is governed by a Joint Steering Committee, made up of parties from both Oxford University and Novo Nordisk. NNRCO itself is led by Professor James D Johnson.
The scientific mission of NNRCO is to conduct world class discovery research to identify new therapeutic targets in type 2 diabetes and related areas. NNRCO will also participate in the training of the next generation of type 2 diabetes research scientists by co-sponsoring students.
NNRCO is a innovative academic-industry hybrid institute, with a focus on discovery research in the pre-competitive space. Collaborative co-creation projects will be co-funded via the Joint Steering Committee.
Between 2017 and 2021, NNRCO will employ up to 100 researchers who will be visitors to Oxford University in various capacities, including Visiting Professors and Industrial Visiting Fellows. These NNRCO researchers will work in new state-of-the-art laboratories in the BioEscalator Building on the Old Road Campus starting mid-2018. Until then, NNRCO has temporary space nearby in the Centre for Cellular & Molecular Physiology building.
- For further information on the Novo Nordisk Fellowship scheme please click here.
- If you would like to contact Novo Nordisk or have any questions please contact Business Development Manager Dr Siobhan Dennis
Below: Artist Impression of new laboratories